Evidence map›Paper›PMID 38187321›Full record

ReviewHeliyon2024

The effectiveness of Kami Guibi-tang for cognitive impairment patients: A retrospective chart review.

Tae-Bin Yim, Gyu-Ri Jeon, Hye-Jin Lee, Kyeong-Hwa Lee, Hye-Min Heo, Han-Gyul Lee, Seungwon Kwon, Seung-Yeon Cho, Seong-Uk Park, Woo-Sang Jung and 3 more

Open access · goldAbstract readReview
In one paragraph

Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Tae-Bin YimStroke and Neurological Disorders Center, Kyung Hee University College of Korean Medicine, Kyung Hee University Hospital at Gangdong, Seoul, South Korea.
Gyu-Ri JeonStroke and Neurological Disorders Center, Kyung Hee University College of Korean Medicine, Kyung Hee University Hospital at Gangdong, Seoul, South Korea.
Hye-Jin LeeDepartment of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul, South Korea.
Kyeong-Hwa LeeDepartment of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul, South Korea.
Hye-Min HeoDepartment of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul, South Korea.
Han-Gyul LeeDepartment of Cardiology and Neurology, Kyung Hee University College of Korean Medicine, Kyung Hee University Medical Center, Seoul, South Korea.
Seungwon KwonDepartment of Cardiology and Neurology, College of Korean Medicine, Kyung Hee University, Seoul, South Korea.
Seung-Yeon ChoStroke and Neurological Disorders Center, Kyung Hee University College of Korean Medicine, Kyung Hee University Hospital at Gangdong, Seoul, South Korea.
Seong-Uk ParkStroke and Neurological Disorders Center, Kyung Hee University College of Korean Medicine, Kyung Hee University Hospital at Gangdong, Seoul, South Korea.
Woo-Sang JungDepartment of Cardiology and Neurology, College of Korean Medicine, Kyung Hee University, Seoul, South Korea.
Sang-Kwan MoonDepartment of Cardiology and Neurology, College of Korean Medicine, Kyung Hee University, Seoul, South Korea.
Chang-Nam KoStroke and Neurological Disorders Center, Kyung Hee University College of Korean Medicine, Kyung Hee University Hospital at Gangdong, Seoul, South Korea.
Jung-Mi ParkStroke and Neurological Disorders Center, Kyung Hee University College of Korean Medicine, Kyung Hee University Hospital at Gangdong, Seoul, South Korea.
Kyung Hee University · KRKyung Hee University Hospital at Gangdong · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: and Purpose: The number of patients with cognitive impairment is increasing worldwide. Therapeutic drugs that slow disease progression are being developed; however, further research is required. This study investigated the effects of Kami Guibi-tang on patients with various types of cognitive decline. Methods: This study was a single-center, retrospective chart review of patients who visited KyungHee University Hospital at Gangdong from January 2015 to March 2022. The study included participants who took Kami Guibi-tang for more than 90 days and were assessed on the Korean version Mini-Mental State Examination (MMSE-K) scores before and after treatment. Participants who received other liquid herbal medicines during the treatment were excluded. The outcome of interest was changed scores in MMSE-K and Short form of Geriatric Depression Scale (S-GDS). Results: A total of 31 participants were included. The total MMSE-K score significantly increased with time and showed a significant increase at 3 and 9 months compared with baseline. Among the MMSE-K subscores, the orientation subscore showed a significant increase at three months compared with baseline, and the attention and calculation subscore showed a significant increase with time. In addition, four participants with vascular dementia showed a significant increase in the total MMSE-K score over time and a significant increase after 9 months compared with baseline. The S-GDS score in 31 participants showed a significant decrease with time and at all time points compared with baseline. Conclusions: Kami Guibi-tang may improve cognitive function in patients with cognitive decline.

Indexed as

Alzheimer's diseaseHerbal medicineKami Guibi-tangMild cognitive impairmentSubjective cognitive declineVascular dementia

Identifiers

PMID38187321
PMCPMC10770547
OpenAlexW4389802893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.